Loading stock…

Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276Market cap $46BPrice $7.0

Country🇨🇳China

SectorHealthcare

IndustryPharmaceuticals

Develops and manufactures cancer drugs and other prescription medicines across China and globally. Controls nearly 10% of China's oncology drug market and exports to over 20 countries including the US.

In Bastion Portfolios?

52W Return-23%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+14%8

Revenue Forecast

Rev CAGR (1y)+10%6

Rev CAGR (3y)+12%7

Rev CAGR (5y)+18%9

Earnings Forecast

EPS Growth Y+1+18%8

EPS Growth Y+2+13%7

EPS Growth Y+3+19%8

Quality

Margins

EBIT Margin24%8

Net Income Margin25%8

Free Cash Flow Margin18%8

Debt

Net Debt/EBITDA-4.610

Efficiency

ROE13%6

ROA12%9

Earnings Stability77

GEAR+AVERAGE66

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)332

P/E Ratio (Forward 3y)262

P/BV4.83

EV Multiples

EV/EBITDA Fwd282

EV/EBIT Fwd292

Yield

Free Cash Flow Yield1.8%4

Dividend Yield0.4%2

Momentum

Short term

1 month return+3%9

3 month return-13%3

YTD return-20%2

Mid term

Price vs 52wHigh66%3

1 year return-34%2

Long term

3 year return+6%3

5 year return-11%3

Risk Shield

Price Risk

Betana–

Volatility33%6

Free Cash Flow

Free Cash Flow Margin18%8

Free Cash Flow Yield1.8%4

Quality

ROCE12%6

Earnings Stability77

Net Debt/EBITDA-4.610

02Growth

Is it actually growing, and how fast?

600276Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Revenue FY25$4.5B

GROWTH RATING↗

STRONG75 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+14%8

Revenue, next 1Y+10%6

Revenue, next 3Y, CAGR+12%7

Revenue, next 5Y, CAGR+18%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+18%8

EPS growth, FY27E+13%7

EPS growth, FY28E+19%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 75% of companies worldwide.

Revenue grew 14%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 12%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 14%/yr over the last 3 years and is set to keep growing around 12%/yr.

The runway holds up: revenue is set to grow 18%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 18%/yr vs revenue 12%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

600276Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Total return Current196%

Price return Current188%

MOMENTUM RATING↗

WEAK21 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+3%9

3-month return-13%3

YTD return-20%2

MID & LONG-TERM▾SCORE

% of 52-week high66%3

1-year return-34%2

3-year return+6%3

5-year return-11%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+3%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+6.4% over three years and -11% over five), behind 70% of the market.

It's down 34% over the past year, now 34% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-13%) and so far this year (-20%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Jiangsu Hengrui Pharmaceuticals Co.,Ltd. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

600276Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Revenue FY25$4.5B

GROWTH RATING↗

STRONG75 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+14%8

Revenue, next 1Y+10%6

Revenue, next 3Y, CAGR+12%7

Revenue, next 5Y, CAGR+18%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+18%8

EPS growth, FY27E+13%7

EPS growth, FY28E+19%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 75% of companies worldwide.

Revenue grew 14%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 12%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 14%/yr over the last 3 years and is set to keep growing around 12%/yr.

The runway holds up: revenue is set to grow 18%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 18%/yr vs revenue 12%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

600276Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Total return Current196%

Price return Current188%

MOMENTUM RATING↗

WEAK21 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+3%9

3-month return-13%3

YTD return-20%2

MID & LONG-TERM▾SCORE

% of 52-week high66%3

1-year return-34%2

3-year return+6%3

5-year return-11%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+3%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+6.4% over three years and -11% over five), behind 70% of the market.

It's down 34% over the past year, now 34% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-13%) and so far this year (-20%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Jiangsu Hengrui Pharmaceuticals Co.,Ltd. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community